Metrope^® GP (Solution) Instructions for Use

Instructions
Dosage forms

ATC Code

A05BA (Drugs for the treatment of liver diseases)

Active Substance

Honey (Ph.Eur. European Pharmacopoeia)

Clinical-Pharmacological Group

Hepatoprotective agent

Pharmacotherapeutic Group

Hepatoprotective agent

Pharmacological Action

It exerts a membrane-stabilizing and antioxidant effect. It possesses hepatoprotective activity and enhances the antitoxic function of the liver.

Indications

Use for the treatment of the following liver conditions:

Fatty liver dystrophy of various etiologies
Chronic hepatitis
Toxic liver lesions

Refer to the ICD codes table for specific diagnostic codes corresponding to these conditions.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
B18	Chronic viral hepatitis
K70	Alcoholic liver disease
K71	Toxic liver disease
K73	Chronic hepatitis, not elsewhere classified
K76.0	Fatty (change of) liver, not elsewhere classified

ICD-11 code	Indication
1E51.Z	Chronic viral hepatitis, unspecified
4A85.00	Drug hypersensitivity-induced liver disease
DB92.0	Non-alcoholic fatty liver disease without steatohepatitis
DB92.Y	Other specified non-alcoholic fatty liver disease
DB92.Z	Non-alcoholic fatty liver disease, unspecified
DB94.Z	Alcoholic liver disease, unspecified
DB95.Z	Drug-induced or toxic liver disease, unspecified
DB97.2	Chronic hepatitis, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer the solution by subcutaneous injection.

For adult patients, the standard dose is 1 ml once per day.

Adhere to the prescribed duration of therapy, which typically ranges from 10 to 20 days.

Do not exceed the recommended daily dose or the total treatment duration.

Adjust the injection site daily to prevent local irritation.

Ensure the solution is clear and free of particulate matter before administration.

Follow aseptic technique during preparation and injection to minimize the risk of infection.

If a dose is missed, administer it as soon as possible on the same day.

Do not administer a double dose to make up for a forgotten one.

The need for a repeated treatment course should be determined by a physician based on clinical assessment.

Adverse Reactions

Allergic reactions are possible following administration. Monitor the patient for signs of hypersensitivity, such as skin rash, itching, or localized reactions at the injection site.

Discontinue use immediately and initiate appropriate therapy if any severe allergic manifestations occur.

Contraindications

Do not administer under the following conditions:

Known hypersensitivity to the drug or any of its components.
History of allergy to bee products, including honey, propolis, or bee venom.

Overdose

No specific information is available on overdose symptoms. Given the composition, the risk of acute toxic effects is considered low.

In case of suspected overdose, discontinue administration and initiate symptomatic and supportive care. Monitor the patient’s clinical status closely.

Drug Interactions

Formal drug interaction studies have not been conducted. No specific pharmacokinetic or pharmacodynamic interactions are currently known or reported.

Exercise caution when co-administering with other medications. Monitor for any unexpected effects due to the lack of comprehensive interaction data.

Special Precautions

It should be used with caution in patients with diabetes mellitus.

Storage Conditions

Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Metrope^® GP [Canon-2, LLC (Russia)]
Solution for subcutaneous administration 4.5 mg/ml: 1 ml ampoules, 5, 10, 20, 25, 50, or 100 pcs.

Marketing Authorization Holder

Canon-2, LLC (Russia)

Dosage Form

Metrope^® GP

Solution for subcutaneous administration 4.5 mg/ml: 1 ml ampoules, 5, 10, 20, 25, 50, or 100 pcs.

Dosage Form, Packaging, and Composition

Solution for subcutaneous administration	1 ml
Honey	4.5 mg

1 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
1 ml – ampoules (5) – contour cell packs (2) – cardboard packs.
1 ml – ampoules (5) – contour cell packs (5) – cardboard packs.
1 ml – ampoules (5) – contour cell packs (10) – cardboard packs.
1 ml – ampoules (10) – contour cell packs (1) – cardboard packs.
1 ml – ampoules (10) – contour cell packs (2) – cardboard packs.
1 ml – ampoules (10) – contour cell packs (5) – cardboard packs.
1 ml – ampoules (10) – contour cell packs (10) – cardboard packs.

Metrope^® GP [Canon-2, LLC (Russia)]
Solution for subcutaneous administration 4.5 mg/1 ml: ampoules, 5 or 10 pcs.

Marketing Authorization Holder

Canon-2, LLC (Russia)

Manufactured By

Dalkhimpharm, JSC (Russia)

Dosage Form

Metrope^® GP

Solution for subcutaneous administration 4.5 mg/1 ml: ampoules, 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for subcutaneous administration in the form of a transparent, colorless or slightly colored liquid without odor.

	1 l
Natural Honey	4.5 g

1 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
1 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.
1 ml – glass ampoules (10) – cardboard boxes.